https://gvhdhub.com

Home | GvHD HubHome | GvHD Hub You need to enable JavaScript to run this app. All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie PolicyYes, I accept cookiesIntroducingNow you can personaliseyour GvHD Hub experience!Bookmark content to read laterSelect your specific areas of interestView content recommended for youCreate My GvHD HubFind out more  TRANSLATEThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.Steering CommitteeAbout UsNewsletterContactVisit:ALL HubAML HubLupus HubLymphoma HubMPN HubMultiple Myeloma HubPsOPsA HubLOADINGYou're logged in! Click here any time to manage your account or log out.Brought to you byLOADINGYou're logged in! Click here any time to manage your account or log out.VIEW ALL CONTENTSteering CommitteeAbout UsNewsletterContactTypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATESVIEW ALLGvHD TypesaGvHDcGvHDGvHDAcute graft-versus-host diseaseGraft-versus-host diseaseChronic graft-versus-host diseaseRiskView all TypesVIEW ALL CONTENTAdd bookmarkIACH 2024 live congress feedStay up to date with the latest developments in GvHD from IACH 2024 Annual Meeting with our live social media coverage.Sep 19, 2024Add bookmarkAddition of ATG to standard prophylaxis reduces incidence of acute and chronic GvHDWe summarize a retrospective, real-world, cohort study that compared ATG + standard GvHD prophylaxis (CSA + MTX) with the standard regimen alone in 210 patients...Sep 18, 2024Add bookmarkImpact of donor age and type in patients with AML undergoing allo-HSCTWe summarize results from a retrospective analysis comparing outcomes of allo-HSCT with young haploidentical donors vs older mismatched unrelated donors, and vice versa, in...Sep 10, 2024Add bookmarkRuxolitinib for treatment of sclerotic cGvHD: Results from a phase II studySclerotic cGvHD is a highly-refractory form of cGvHD associated with high morbidity. A multicenter phase II trial of 47 adult patients with corticosteroid-refractory...Sep 6, 2024Mohamad Mohty"The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information."Mohamad Mohty"The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information."Your opinion mattersHCPs, what is your preferred format for educational content on the GvHD Hub?Publication summariesVisual abstractsExpert videosExpert podcasts0 votes - 88 days left ...EBMT 2024view moreAdd bookmark Symposium | Early intervention and use of ECP combinations in cGvHDFlorent Malard, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, delivered a presentation during the GvHD symposium at the...Jul 23, 2024Add bookmarkSymposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-upHere, we share a presentation by Zinaida Perić, University of Rijeka, Rijeka, HR, as part of the GvHD...Jul 19, 2024Add bookmarkSymposium | The long-term burden of cGvHDDuring the GvHD symposium at the 50th Annual Meeting of the EBMT, Bipin Savani, Vanderbilt University Medical Center, Nashville, US, explored the long-term...Jul 15, 2024Add bookmarkSymposium | A brief overview and history of ECPThe GvHD Hub symposium at the 50th Annual Meeting of the EBMT was chaired by Mohamad Mohty, and featured presentations by Florent Malard, Zinaida Perić,...Jul 12, 2024EHA 2024view moreAdd bookmarkPTCy-based GvHD prophylaxis following MMUD peripheral blood stem cell transplantation: Results from the phase II ACCESS trialWe summarize results from the phase II ACCESS trial of PTCy-based GvHD...Aug 1, 2024Add bookmarkBelumosudil in Japanese patients with cGvHD: Results from a phase III trialHere, we summarize results from a phase III trial of belumosudil as a second or subsequent line of therapy in Japanese...Jul 22, 2024Most ReadAdd bookmarkECP for the treatment of cGvHD: Emerging data and clinical management considerations Add bookmarkRuxolitinib in pediatric patients with chronic GvHD: Interim results from REACH5Add bookmarkPTCy-based GvHD prophylaxis following MMUD peripheral blood stem cell transplantation: Results from the phase II ACCESS trialAdd bookmarkECP: Clinical considerations for the treatment of cGvHDExtracorporeal photopheresisview moreAdd bookmarkECP for the treatment of cGvHD: Emerging data and clinical management considerations In cGvHD, immunosuppressant corticosteroids remain a first-line treatment option. ECP is recommended as a...Sep 3, 2024Add bookmark Future perspectives of ECP for GvHD treatmentThe GvHD Hub were pleased to speak to Andrew Gennery, Newcastle University and Great North Children’s Hospital, UK, and Chair of the UK Photopheresis...Aug 9, 2024Add bookmark Symposium | Early intervention and use of ECP combinations in cGvHDFlorent Malard, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, delivered a presentation during the GvHD symposium at the...Jul 23, 2024Add bookmarkSymposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-upHere, we share a presentation by Zinaida Perić, University of Rijeka, Rijeka, HR, as part of the GvHD...Jul 19, 2024Most ViewedAdd bookmark Future perspectives of ECP for GvHD treatmentAdd bookmark Symposium | Early intervention and use of ECP combinations in cGvHDAdd bookmarkSymposium | A brief overview and history of ECPAdd bookmarkManagement of drug-related adverse events in patients with steroid-refractory cGvHDBrought to you byDelivering streamlined independent medical education to enhance clinical practiceIn partnership withThank you to the funders of the GvHD Hub. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.Interested in becoming a supporter? Please contact us.Terms and ConditionsCookie PolicyPrivacy PolicyNewsletterCopyright ©GvHD Hub. 2018-2024. All rights reserved.All content on this site is intended for healthcare professionals only.enenhttps://gvhdhub.com

Editeu el vostre lloc?

Què estàs fent?